65-OR: Age at Type 2 Diabetes Diagnosis and Mortality and Cardiovascular Risks, and Years of Life Lost in South Asians

Introduction and Objective: South Asians develop type 2 diabetes (T2D) earlier than others. We investigated associations between age at T2D diagnosis and risks of all-cause and CVD mortality, non-fatal CVD events, and years of life lost (YLL). Methods: We analyzed data from 21,861 CARRS cohort participants. T2D was defined as self-reported diagnosis, T2D treatment, fasting plasma glucose ≥126 mg/dL, 2-h plasma glucose >200 mg/dL, or HbA1c ≥6.5%. Participants were grouped by age at diagnosis: 20-29, 30-39, 40-59, and ≥60 years. Cox regression models estimated risks, adjusting for demographics and clinical factors. YLL was calculated using India’s Individual Annuitant Mortality Table. Results: Among 21,861 participants (mean age 43.6 years; 44.5% male), 6,396 had T2D (5,295 prevalent; 181 incident). Over 14 years (132,293 person-years), 2,121 deaths (809 CVD) and 336 non-fatal CVD events occurred. Earlier T2D diagnosis was linked to higher all-cause mortality vs. those without T2D: HR 2.2 (20-29), HR 2.0 (30-39), HR 1.4 (40-59), HR 0.9 (≥60). Similar patterns were seen for CVD mortality and non-fatal CVD events (Table). T2D caused an average 12-year life loss, with YLL increasing for earlier diagnosis: 19.2 (20-29), 16.8 (30-39), 12.2 (40-59), and 6.3 (≥60). Conclusion: T2D was linked to greater years of life lost and higher mortality risks, especially in younger individuals, highlighting the need for early detection and management in South Asians. Disclosure R. Jagannathan: None. A.S. Oguntade: None. M. Deepa: None. D. Kondal: None. R. Anjana: None. S.A. Patel: None. R.M. Carrillo-Larco: None. S. Mohan: None. M.K. Ali: Advisory Panel; Eli Lilly and Company. A.A. Quyyumi: None. D. Prabhakaran: None. V. Mohan: Speaker's Bureau; Novo Nordisk. Advisory Panel; Abbott. Research Support; Servier Laboratories. Speaker's Bureau; USV Private Limited, Sanofi, Medtronic, Eli Lilly and Company. K. Narayan: None. N. Tandon: None. Funding The Center for cArdiometabolic Risk Reduction in South Asia study were supported by grants from the National Heart, Lung, and Blood Institute (HHSN2682009900026C, P01HL154996), National Institutes of Health (NIH), National Institute on Aging, NIH (R01-AG89759), and National Institute of Diabetes and Digestive and Kidney Diseases (R01DK139632), NIH.